Abbott received permission from the Subject Expert Committee to market a fixed dose combination (FDC) of Lidocaine and Diltiazem, after detailed deliberation by committee.
Abbott has presented a Phase III clinical trial report before the committee and after detailed deliberation, the committee recommended grant of permission for manufacturing and marketing of the proposed FDC.
- Read more about Abbott got CDSCO panel nod to market Lidocaine and Diltiazem combination
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/abbott-got-cdsco-panel-nod-to-market-lidocaine-and-diltiazem-combination
No comments:
Post a Comment